Systematic Multi-domain Alzheimer's Risk Reduction Trial
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Alzheimer Disease, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 70 - 89 |
| Updated: | 9/27/2018 |
| Start Date: | August 30, 2018 |
| End Date: | January 31, 2021 |
Multidomain Alzheimers Risk Reduction Study (MARRS) Pilot
The primary goal of this randomized controlled trial (RCT) is to pilot-test a personalized,
pragmatic, multi-domain Alzheimer's disease risk reduction intervention in a U.S. integrated
healthcare delivery system.
pragmatic, multi-domain Alzheimer's disease risk reduction intervention in a U.S. integrated
healthcare delivery system.
We propose to randomize 200 higher-risk older adults (age 70-89 with low-normal performance
on cognitive testing and 2+ modifiable risk factors that will be targeted by our
intervention) to a two-year Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT)
intervention or a Health Education (HE) control.
The SMARRT team will work with participants randomized to the intervention arm to develop a
tailored action plan to address risk reduction. Targeted areas will include: increasing
physical, mental and social activities; controlling cardiovascular risk factors (diabetes,
hypertension); quitting smoking; reducing depressive symptoms; improving sleep;
neuroprotective diet; and decreasing use of potentially harmful medications. HE participants
will receive periodic handouts on these topics by mail.
on cognitive testing and 2+ modifiable risk factors that will be targeted by our
intervention) to a two-year Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT)
intervention or a Health Education (HE) control.
The SMARRT team will work with participants randomized to the intervention arm to develop a
tailored action plan to address risk reduction. Targeted areas will include: increasing
physical, mental and social activities; controlling cardiovascular risk factors (diabetes,
hypertension); quitting smoking; reducing depressive symptoms; improving sleep;
neuroprotective diet; and decreasing use of potentially harmful medications. HE participants
will receive periodic handouts on these topics by mail.
Inclusion Criteria:
- 70-89 Years of Age
- Fluent in the English Language
- Low-normal performance on a brief telephone cognitive screen, measured using the
Cognitive Abilities Screening Instruments (CASI). Low-normal scores are defined as
26-29.
- Has at least two additional risk factors that will be targeted by the intervention.
Exclusion Criteria:
- Residing in a skilled nursing or rehabilitation facility
- Receiving palliative care or hospice services
- Charlson comorbidity index score of greater than 5
- Bipolar illness or schizophrenia
- Current alcohol or drug use disorder
- Receiving chronic opioid therapy
- Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis
- Severe visual or hearing impairment
- Requests not to be contacted or not to have their medical record reviewed for research
- Prior evidence of dementia
We found this trial at
1
site
Click here to add this to my saved trials
